The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia |
Lee, Joong-Yub
(Department of Preventive Medicine, Seoul National University College of Medicine)
Choi, Nam-Kyoung (Department of Preventive Medicine, Seoul National University College of Medicine, Medical Research Center, Seoul National University) Jung, Sun-Young (Department of Preventive Medicine, Seoul National University College of Medicine) Kim, Ye-Jee (Department of Preventive Medicine, Seoul National University College of Medicine) Seong, Jong-Mi (Department of Preventive Medicine, Seoul National University College of Medicine) Oh, Seung-June (Department of Urology, Seoul National University College of Medicine) Park, Byung-Joo (Department of Preventive Medicine, Seoul National University College of Medicine) |
1 | Han KS, Hong SJ, Chung BH, Changing trends in the management of benign prostatic hyperplasia during recent 5 years, Korean J Urol 2005; 46(5):458-462 |
2 | AUA Practice Guidelines Committee, Guideline on the management of benign prostatic hyperplasia, J Urol 2003; 170(2 Pt 1): 530-547 DOI |
3 | Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha blockers and the risk of hip/femur fractures, J Intern Med 2003; 254(6): 548-554 DOI ScienceOn |
4 | Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: Critical systematic review, J Gerontol A Biol Sci Med Sci 2007; 62(10): 1172-1181 DOI PUBMED ScienceOn |
5 | Stoevelaar HJ, McDonnell J, Changing therapeutic regimens in benign prostatic hyperplasia, Pharmacoeconomics 2001;19(2):131-153 DOI ScienceOn |
6 | Macdonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects, BJU Int 2004; 94(9): 1263-1270 DOI ScienceOn |
7 | Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events, Am J Epidemiol 1991; 133(2):144-153 DOI PUBMED ScienceOn |
8 | Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H. Initiation of nonselective alpha1 antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study, Clin Ther 2001;23(5):727-743 DOI ScienceOn |
9 | Arrighi HM, Metter EJ, Guess HA, Fozzard JL, Natural history of benign prostatic hyperplasia and risk of prostatectomy, Urology 1991; 38(1 Suppl): 4-8 DOI ScienceOn |
10 | Maclure M. Why me? versus why now? - differences between operational hypothesis in case control versus case-crossover studies, Pharmacoepidemiol Drug Saf 2007;16(8):850-853 DOI PUBMED ScienceOn |
11 | McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM, Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology, Pharmacoepidemiol Drug Saf 1998;7(4): 275-280 DOI ScienceOn |
12 | Hall GC, McMahon AD, Comparative study of modified release alpha blocker exposure in elderly patients with fractures, Pharmacoepidemiol Drug Saf 2007; 16(8):901-907 DOI ScienceOn |
13 | Djavan B, Chapple C, Milani S, Marberger M, State of the art on the efficacy and tolerability of the alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, J Urol 2004; 64(6): 1081-1088 DOI ScienceOn |
14 | Korea National Statistical Office, Korean Census 2005. Daejeon: Korea National Statistical Office [cited 2008 Oct 11], Available from: URL: http://www.kosis.kr |
15 | McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al, The long-term effect of doxazosin, finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med 2003; 349(25):2387-2398 DOI ScienceOn |
16 | Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, et al. A high risk group for prostatism: A population-based epidemiological study in Korea, Br J Urol 1997; 79(5):736-741 DOI PUBMED ScienceOn |
17 | Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on a1-adrenoceptor antagonists. BJU Int 2005; 95 Suppl 4:29-36 DOI ScienceOn |